Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Probiotic 6600
- Development stage
- Unknown
- Lead developer
- Changhai Hospital
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Probiotic 6600 is a live biotherapeutic product consisting of a specific commensal bacterial strain being developed by Changhai Hospital as an adjuvant therapy for inflammatory bowel diseases, including ulcerative colitis and Crohn's disease. The strain is characterized by its unique ability to synthesize adhesins and exopolysaccharides, which facilitate its function as a core commensal in the human gut. Its therapeutic effects are mediated through several mechanisms: the regulation of the Treg/Th17 immune balance via the production of short-chain fatty acids (SCFAs), the inhibition of the NF-κB inflammatory cascade through the activation of the TLR2/MyD88 pathway, and the enhancement of intestinal barrier function by upregulating zonula occludens-1 (ZO-1). Additionally, Probiotic 6600 specifically metabolizes arabinoxylan into indole lactate, an anti-inflammatory metabolite that provides therapeutic value within the colitis microenvironment. It is administered orally as enteric-coated capsules containing 10^11 CFU.
- Other names
- Probiotics 6600Probiotics6600Probiotics-6600
02
Targets
NF-κBTLR2 (Toll-like Receptor 2)TJP1 (Tight junction protein 1 (ZO-1))MYD88 (Myeloid differentiation primary response protein MyD88)
Beyond the preview
Go deeper on Probiotic 6600.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Probiotic 6600.